In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $6.42, marking a +1.58% move from the previous day. This move lagged the S&P 500's daily gain of 1.83%. On the other hand, the Dow registered a gain of 1.65%, and the technology-centric Nasdaq increased by 2.45%.Shares of the biotechnology company witnessed a loss of 11.24% over the previous month, trailing the performance of the Medical sector with its loss of 3.48% and the S&P 500's loss of 3.31%.The upcoming earnings release of Rec ...

Shares of Recursion Pharmaceuticals (RXRX) have gained 4% over the past four weeks to close the last trading session at $7.26, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $9.29 indicates a potential upside of 28%.The average comprises seven short-term price targets ranging from a low of $6 to a high of $11, with a standard deviation of $1.70. While the lowest estimate indica ...

REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitors REC-4539, a potential best-in-class LSD1 inhibitor, is the first designed to be reversible and CNS penetrant for small-cell lung cancer Salt Lake City, UT, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced tod ...

Clinical Trial Approvals - The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has cleared a clinical trial application (CTA) for a Phase 1 clinical trial of REC-3565, a potential best-in-class MALT1 inhibitor for B-cell malignancies [1] - The U S Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for a Phase 1/2 clinical trial of REC-4539, a potential best-in-class LSD1 inhibitor for small-cell lung cancer (SCLC) and other potential indications [1] Target Populations - The total addressable population for REC-3565 includes approximately 41,000 relapsed and/or refractory (R/R) patients with chronic lymphocytic leukemia (CLL) and B-cell lymphomas in the US+EU5 annually [1][2] - The total addressable population for REC-4539 in the US+EU5 for extensive stage SCLC is approximately 45,000 patients annually [1][8] Mechanism of Action - REC-3565 is a highly selective MALT1 inhibitor without significant off-target inhibition of UGT1A1, which could enhance combination therapy by mitigating potential risks of drug-drug interaction and hyperbilirubinaemia [1][4] - REC-4539 is a reversible LSD1 inhibitor designed to penetrate the brain, potentially addressing a critical unmet need in small-cell lung cancer [1][6] Preclinical Data - REC-3565 has shown tumor growth inhibition in a range of hematological xenograft models as both a single agent and in combination with BTK inhibitors, with durable tumor eradication observed in combination with zanubrutinib in an ABC-DLBCL xenograft model [5] - REC-4539 has demonstrated dose-dependent tumor inhibition in an SCLC xenograft model with brain penetration and a reversible mechanism [13] Clinical Trial Timelines - The first patient is expected to be dosed in the Phase 1 EXCELERIZE clinical trial for REC-3565 in Q1 2025 [7] - The first patient is expected to be dosed in the Phase 1/2 ENLYGHT clinical trial for REC-4539 in H1 2025 [9] Company Overview - Recursion is a clinical stage TechBio company leveraging the Recursion OS platform, which integrates advanced AI capabilities to identify and optimize molecules with unique properties [1][10] - The company is headquartered in Salt Lake City and has offices in Toronto, Montréal, London, and the San Francisco Bay Area [11]

Salt Lake City, UT, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announces that co-founder and CEO Chris Gibson, PhD will present at the upcoming 43rd Annual JP Morgan Healthcare Conference in San Francisco. On Monday, January 13, 7:30am PT (10:30am ET), at the Westin St. Francis in the Elizabethan Room A/B, Dr. Gibson will present updates on Recursion’s latest clinical pipeline, partnerships, and plat ...

Successfully navigating the stock market requires patience and a long-term perspective. The key is sticking to a consistent plan and making regular contributions to a retirement account, allowing the power of compounding to work its magic over time.Nevertheless, there's an undeniable allure in searching for potential multibagger stocks. Something is captivating about companies with disruptive innovations, whose stocks could be on the cusp of rapid growth and capable of delivering life-changing returns to sh ...

The artificial intelligence (AI) field has been grabbing many headlines on Wall Street in the past two years. Will this trend continue in 2025? It's hard to say, but whether or not it does, specific AI-focused companies could make significant progress and see their shares soar as a result.Recursion Pharmaceuticals (RXRX -0.98%) could be one of them. The AI-focused biotech has several potential catalysts next year. Let's figure out whether investing in Recursion Pharmaceuticals ahead of 2025 is worth it.Some ...

Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that on December 19, 2024, the Compensation Committee of Recursion's Board of Directors approved the grant of inducement restricted stock unit (RSU) awards covering 7,952,836 shares of its class A common stock in the aggregate to 230 new employees under Recursion's 2024 Inducement Equit ...

Recursion Pharmaceuticals (NASDAQ: RXRX ) is a technology-powered biopharmaceutical company, which is harnessing the power of artificial intelligence and machine learning to identify novel therapeutic targets for conditions with unmet clinical needs, accelerate drug discovery and reduceOriginally a Biologist, M.Sc in Biomedicine, PhD in Bioengineerings, and +20 years experience in the research and development of novel Cell & Gene Therapies (CGT) tackling several clinical needs including orthopaedics and rar ...

SALT LAKE CITY, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today the release of OpenPhenom-S/16, a publicly available foundation model in Google Cloud's Vertex AI Model Garden. This will enable Life Science companies to use OpenPhenom-S/16 on Google Cloud when building apps that require microscopy data to assess the effectiveness of drug treatments, analyze cultures, study tissues and ultima ...